FDA Clearance Tracker · K260065
SAFElife T-Dip Multi-Drug Urine Test Panel; SAFElife T-Dip Multi-Drug Urine Test Panel Dx
Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Apr 28, 2026
Substantially Equivalent
Time to decision
109 days
Received Jan 9, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K260065
- Device name
- SAFElife T-Dip Multi-Drug Urine Test Panel; SAFElife T-Dip Multi-Drug Urine Test Panel Dx
- Applicant
- Guangzhou Wondfo Biotech Co., Ltd.
- Applicant location
- Guangzhou, CN
- Received
- Jan 9, 2026
- Decided
- Apr 28, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Test, Amphetamine, Over The Counter (NFT)
- Device class
- Class II
- Regulation
- 21 CFR 862.3100
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code NFT. The earliest in FDA's data is K170049, decided May 2, 2017.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K260065
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Guangzhou Wondfo Biotech Co., Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252550 · Decided Nov 18, 2025 · 97 days after receipt
Device type: Test, Amphetamine, Over The Counter (NFT) · Laboratory Medicine & Pathology
K251289 · Decided Oct 22, 2025 · 180 days after receipt
Device type: Simple Point-Of-Care Device To Directly Detect Sars-Cov-2 Viral Targets From Clinical Specimens In Near-Patient Settings (QVF) · Laboratory Medicine & Pathology
K241317 · Decided Sep 30, 2024 · 143 days after receipt
Device type: Over-The-Counter Covid-19 Antigen Test (QYT) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.